Science

Apr 7, 2025, 09:36

Myeloma Paper of the Day, April 7th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Venetoclax combos in relapsed/refractory myeloma – ORR of 57% (64% in t (11;14), 26% in non-t (11;14) with hi BCL2), PFS 9.4 mos (11.8 for t (11;14) vs. 2.9 months for non); presence of del (17p) or +1q reduced PFS to 7.7 mos.”

“Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes”

Authors: Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, Leif Bergsagel, Linda Baughn, Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar et al.

More posts featuring Robert Orlowski.

Abiola Bolarinwa cancer Leif Bergsagel Linda Baughn Madhu Nagaraj multiple myeloma Myeloma Paper of the Day Nadine Abdallah OncoDaily Oncology Rafael Fonseca relapsed/refractory multiple myeloma Robert Orlowski RRMM Saurabh Zanwar Shaji Kumar Sikander Ailawadhi Vincent Rajkumar

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025